Literature DB >> 15183191

Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver.

De-Xiang Xu1, Wei Wei, Mei-Fang Sun, Cheng-Yi Wu, Jian-Ping Wang, Ling-Zhen Wei, Cheng-Fan Zhou.   

Abstract

Pregnane X receptor (PXR) is a member of the nuclear receptor superfamily that regulates target gene transcription in a ligand-dependent manner. The in vivo effects of lipopolysaccharide (LPS) on expression of PXR and its target gene cytochrome P450 3A (CYP3A) in mouse liver were investigated in this study. Mice were injected intraperitoneally with different doses of LPS (0.1-5.0 mg/kg). PXR and CYP3A11 mRNA levels were measured using reverse transcription polymerase chain reaction. Results indicate that LPS significantly inhibits the expression of PXR mRNA in a dose-dependent manner, followed by suppression of CYP3A11 mRNA in mouse liver. LPS also represses the upregulation of CYP3A11 mRNA levels and erythromycin N-demethylase (ERND) catalytic activity in mice pretreated with PXR ligands dexamethasone, rifampicin, mifepristone, and phenobarbital. LPS-induced downregulation of PXR and CYP3A11 mRNA in liver was significantly attenuated in mice pretreated with gadolinium chloride, a selective Kupffer cell toxicant. Pretreatment with a single dose of gadolinium chloride (10 mg/kg) also significantly attenuated LPS-induced downregulation of dexamethasone-, rifampicim-, mifepristone-, and phenobarbital-inducible, CYP3A11 mRNA expression and ERND activity in mouse liver. Furthermore, LPS-induced downregulation of PXR and CYP3A11 mRNA was significantly attenuated in mice pretreated with allopurinol, an inhibitor of xanthine oxidase, and diphenyleneiodonium chloride, an inhibitor of NADPH oxidase. Allopurinol and diphenyleneiodonium chloride pretreatment also attenuated the repressive effects of LPS on dexamethasone-, rifampicin-, mifepristone-, and phenobarbital-inducible CYP3A11 mRNA expression and ERND catalytic activity in mouse liver. However, aminoguanidine, a selective inhibitor of inducible nitric oxide synthase, has no effect on LPS-induced downregulation of PXR and CYP3A11 mRNA. Finally, LPS-induced downregulation of PXR and CYP3A11 mRNA was prevented in mice pretreated with either N-acetylcysteine or ascorbic acid. These antioxidants also prevented the repressive effects of LPS on dexamethasone-, rifampicin-, mifepristone-, and phenobarbital-inducible CYP3A11 mRNA expression and ERND catalytic activity in mouse liver. These results indicate that Kupffer cells contribute to LPS-induced downregulation of PXR and CYP3A in mouse liver. Reactive oxygen species, produced possibly by NADPH oxidase and perhaps by xanthine oxidase, are involved in LPS-induced downregulation of nuclear receptor PXR and its target gene CYP3A in mouse liver. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183191     DOI: 10.1016/j.freeradbiomed.2004.03.021

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  17 in total

Review 1.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

2.  Protective effects of IL-4 on Bacillus Calmette-Guerin and lipopolysaccharide induced immunological liver injury in mice.

Authors:  Nan N Zhang; Nong Y Huang; Xi K Zhou; Xiao L Luo; Chang Y Liu; Yan Zhang; Ji Qiu; Yin B Zhang; Xiu Teng; Can Luo; Xian C Chen; Bing Kan; Yong Q Mao; Ai P Tong; Yu Q Wei; Jiong Li
Journal:  Inflamm Res       Date:  2011-09-24       Impact factor: 4.575

3.  Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen.

Authors:  Ryan D Kinloch; Choon-Myung Lee; Nico van Rooijen; Edward T Morgan
Journal:  Biochem Pharmacol       Date:  2011-05-06       Impact factor: 5.858

Review 4.  The role of inflammation in cholestasis: clinical and basic aspects.

Authors:  Astrid Kosters; Saul J Karpen
Journal:  Semin Liver Dis       Date:  2010-04-26       Impact factor: 6.115

5.  Integrin Receptors Play a Key Role in the Regulation of Hepatic CYP3A.

Authors:  Kristina Jonsson-Schmunk; Piynauch Wonganan; Jin Huk Choi; Shellie M Callahan; Maria A Croyle
Journal:  Drug Metab Dispos       Date:  2016-02-11       Impact factor: 3.922

6.  Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes.

Authors:  Romi Ghose; Tao Guo; Jesus G Vallejo; Adarsh Gandhi
Journal:  Drug Metab Dispos       Date:  2011-02-08       Impact factor: 3.922

7.  Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells.

Authors:  Seong Keun Kim; Young Mi Kim; Chung Eun Yeum; Song-Hyo Jin; Gue Tae Chae; Seong-Beom Lee
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

8.  Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform.

Authors:  Thomas J Long; Patrick A Cosgrove; Robert T Dunn; Donna B Stolz; Hisham Hamadeh; Cynthia Afshari; Helen McBride; Linda G Griffith
Journal:  Drug Metab Dispos       Date:  2016-09-12       Impact factor: 3.922

9.  Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid.

Authors:  Romi Ghose; Tao Guo; Nadia Haque
Journal:  Arch Biochem Biophys       Date:  2008-10-08       Impact factor: 4.013

Review 10.  Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.

Authors:  Satyanarayana R Pondugula; Hanqing Dong; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.